Ixabepilone

A semisynthetic Epothilone B analogue and potent, orally active microtubule stabilizer; shows a broad spectrum of activity against a panel of tumor cell lines in vitro (IC50=1.4-34.5 nM), retains the antineoplastic activity against human cancers that are resistance to paclitaxel both in vitro and in vivo.Breast Cancer Approved (In Vitro) :BMS-247550 is a highly potent cytotoxic agent capable of killing cancer cells at low nanomolar concentrations and retains its antineoplastic activity against human cancers that are naturally insensitive to paclitaxel or that have developed resistance to paclitaxel. (In Vivo) :BMS-247550 demonstrates antitumor activity that is superior to paclitaxel in both paclitaxel-resistant and -sensitive tumors. BMS-247550 is more efficacious than paclitaxel in all five paclitaxel-resistant tumors evaluated in this study (four human and one murine) : the clinically derived paclitaxel resistant Pat-7 ovarian carcinoma, the A2780Tax ovarian carcinoma that is resistant to paclitaxel because of tubulin mutations, theHCT116/VM46 MDR colon carcinoma, the clinically derived paclitaxel-resistant Pat-21 breast carcinoma, and the murine fibrosarcoma M5076. Against three paclitaxel-sensitive human tumor xenografts, BMS-247550 produces antitumor activity equivalent to paclitaxel: A2780 human ovarian carcinoma, HCT116, and LS174T human colon carcinoma.

219989-84-1

Azaepothilone B | BMS-247550 | BMS247550

Pharmacology & Drug Discovery

>98% (HPLC)

10 mM in DMSO

O=C (C[C@@H]1O) N[C@H] (/C (C) =C/C2=CSC (C) =N2) C[C@H]3[C@@] (O3) (C) CCC[C@H] (C) [C@H] (O) [C@@H] (C) C (C1 (C) C) =O

C27H42N2O5S

506.6978

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.